<?xml version="1.0" encoding="UTF-8"?>
<ref id="b63-ijmm-46-02-0489">
 <label>63</label>
 <element-citation publication-type="web">
  <person-group person-group-type="author">
   <name>
    <surname>Farag</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Boys</surname>
    <given-names>IN</given-names>
   </name>
   <name>
    <surname>Eitson</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Ohlson</surname>
    <given-names>MB</given-names>
   </name>
   <name>
    <surname>Fan</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>McDougal</surname>
    <given-names>MB</given-names>
   </name>
   <name>
    <surname>Ahmed</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Schoggins</surname>
    <given-names>JW</given-names>
   </name>
  </person-group>
  <article-title>Identification of atovaquone, quabain and mebendazole as FDA approved drugs Tar-geting SARS-CoV-2 (Version 4)</article-title>
  <year>2020</year>
  <source>ChemRxiv</source>
  <comment>Preprint </comment>
  <pub-id pub-id-type="doi">10.26434/chemrxiv.12003930.v4</pub-id>
 </element-citation>
</ref>
